TCRX 8-K: SEC filing

Filed with the SEC on Nov 12, 2026 · accession 0001193125-26-456865

TCRX filed a 8-K (current report) with the SEC on Nov 12, 2026. TScan Therapeutics furnished a Form 8-K announcing its financial results for the third quarter ended September 30, 2026, via an attached press release.

Summary of the filing

TScan Therapeutics furnished a Form 8-K announcing its financial results for the third quarter ended September 30, 2026, via an attached press release. The filing is a routine quarterly earnings disclosure under Item 2.02.

For details, click here →How to read a 8-K →

Key details

RegistrantTScan Therapeutics, Inc.

Chief executive officerGavin MacBeath, Ph.D.

✦ Ask GOAX AI about this filing — what it means for TCRX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for TCRX?

Click here

Frequently asked questions

What did TCRX file with the SEC on Nov 12, 2026?

TCRX filed a 8-K (SEC filing). TScan Therapeutics furnished a Form 8-K announcing its financial results for the third quarter ended September 30, 2026, via an attached press release. The filing is a routine quarterly earnings disclosure under Item 2.02.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other TCRX SEC filings

Get alerts when TCRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

TCRX overview TCRX analysis TCRX news Latest SEC filings